Neoadjuvant chemotherapy with MVC (methotrexate, vinblastine, cisplatin)in the treatment of infiltrating transitional carcinoma of the bladder

• Published in: Archivio italiano di urologia, nefrologia, andrologia Vol. 62; no. 2; p. 237
• Main Authors: Campo, B, Torelli, T, Leidi, G L, Corrada, P, Bacchioni, A M, Ordesi, G, Zanitzer, L
• Format: Journal Article
• Language: Italian
• Published: Italy 01-06-1990
• Subjects: Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carcinoma, Transitional Cell - drug therapy; Carcinoma, Transitional Cell - pathology; Carcinoma, Transitional Cell - surgery; Cisplatin - administration & dosage; Combined Modality Therapy; Drug Evaluation; Female; Follow-Up Studies; Humans; Male; Methotrexate - administration & dosage; Neoplasm Staging; Prospective Studies; Urinary Bladder Neoplasms - drug therapy; Urinary Bladder Neoplasms - pathology; Urinary Bladder Neoplasms - surgery; Vinblastine - administration & dosage
• ISSN: 1120-8538

Of 19 patients with advanced transitional bladder cancer (T2-T4, N0-N+, M0) who received two or three cycles of pre-emptive MVC (Methotrexate, Vinblastine, Cisplatin), pathological partial (PR) and complete (CR) remissions were observed in 67% (50% and 17% respectively). The toxicity of chemotherapy was generally acceptable but 5 patients required hospitalization for neutropenia and thrombopenia . In one of them chemotherapy was stopped for severe sepsis. No death was observed. In 11 patients follow-up is greater than 12 months. In this group, 10 patients are actually alive and disease-free, while the other one was dead owing to brain metastasis, after eight months from surgery.